Rochester, United States
Research view
Diffuse large B-cell lymphoma: who works on it
Groups that published on this disease or run trials on it, from public registries and publications. Researchers appear by name only once their profile is published.
Find fellow researchers
One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.
- All targets
- CD19 42
- CD20 22
- BCL-2 13
- MYC 10
- PD-1 12
- BTK 10
- TP53 7
- PD-L1 3
- CD22 7
- STAT3 0
- CD30 5
- CD47 0
- PI3K 0
- EZH2 1
- LAG-3 0
- ALK 0
- CTNNB1 0
- JAK 0
- STING 0
- BCMA 2
- EGFR 0
- METTL3 0
- mTOR 0
- AKT 0
- CD38 0
- IL-6 0
- JNK 0
- MMP-9 0
- PKM2 0
- PRMT5 0
- TIGIT 1
- TIM-3 0
- ABL1 0
- ARID1A 1
- ATM 0
- BRAF 0
- BRCA1 1
- BRCA2 1
- CCR5 0
- CD40 0
- CDKN2A 0
- CTLA-4 0
- CXCR4 0
- FGFR 0
- FTO 0
- GPX4 0
- HDAC 0
- IL-1 0
- IL-15 0
- MYCN 0
- NLRP3 0
- NOTCH1 1
- PARP 0
- PINK1 0
- PPAR 0
- RAS 0
- SHP2 0
- SIRT1 0
- TERT 0
- TFEB 0
EU-13 is a filter, not a ranking: it only narrows the list.
Houston, United States
New York, United States
Shanghai, China
New York, United States
Boston, United States
Beijing, China
Tampa, United States
Duarte, United States
Hangzhou, China
Tianjin, China
Guangzhou, China
Shanghai, China
Cambridge, United States
Wuhan, China
Chengdu, China
Paris, France
Shanghai, China
Paris, France
Philadelphia, United States
Cleveland, United States
Hangzhou, China
Columbus, United States
Shanghai, China
24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.
Who stopped a trial, and why
Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.
Suspended
Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL
“Accrual met”Registry text, quoted unchanged. Source
Terminated
“Sponsor decided to end the study”Registry text, quoted unchanged. Source
Suspended
“Insufficient funding”Registry text, quoted unchanged. Source
Terminated
“This decision to close the study was made following interactions with regulatory authorities and in consideration of the challenges associated with this patient population. No safety information contributed to this decision.”Registry text, quoted unchanged. Source
Terminated
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
“This decision is due to a company business decision with strategy change on the BGB-21447 development in B-cell malignancies and is not driven by safety concerns.”Registry text, quoted unchanged. Source
Terminated
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
“The trial closed early due to slow accrual.”Registry text, quoted unchanged. Source
Terminated
“No longer a research question to answer.”Registry text, quoted unchanged. Source
Terminated
“Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and Data Safety Monitoring Board recommendations.”Registry text, quoted unchanged. Source
Terminated
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
“Funding”Registry text, quoted unchanged. Source
Withdrawn
“Lack of accrual”Registry text, quoted unchanged. Source
Trials that share participant data
Trials whose registry record says individual participant data (IPD) will be shared.
Search by method
Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.
- Single-Cell Analysis 9
- Mendelian Randomization Analysis 6
- CRISPR-Cas Systems 1
- Gene Expression Profiling 49
- Sequence Analysis, RNA 1
- Whole Genome Sequencing 2
- Exome Sequencing 3
- Proteomics 4
- Flow Cytometry 7
- Immunohistochemistry 36
- Liquid Biopsy 1
- Circulating Tumor DNA 12
- Xenograft Model Antitumor Assays 30
- Positron-Emission Tomography 15
- Magnetic Resonance Imaging 28
- Machine Learning 11
- Deep Learning 9
- Cohort Studies 15
- Genome-Wide Association Study 4
Paste an abstract
See which targets of this disease your abstract mentions, and go to the people working on them.
Matched in your browser only. The text is not sent, saved or logged.
Sources: ClinicalTrials.gov, EU CTR, OpenAlex, PubMed. Machine-matched links are labelled.